Wisconsin Joins Federal Privacy Lawsuit Against Hims And Hers

Wisconsin joined a federal lawsuit against Hims & Hers Health, alleging the telehealth provider shared sensitive health data with third parties and misled customers on subscriptions. The FTC and six other states are also involved. Hims denies the claims, stating it provides clear information to customers.

Original reporting
Published Nov 14, 2026, 3:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 3:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$HIMS
Bearish
high confidence
Mentioned
$HIMS
Relevance
7/10
AlphAI data visualization · based on urbanmilwaukee.com
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The lawsuit introduces legal and reputational risk, likely prompting short‑term sell pressure while investors monitor regulatory outcomes.

02

Market read

First disclosure of a significant privacy enforcement action against a listed telehealth firm, creating immediate downside risk for the stock and sector‑wide privacy concerns.

03

What to watch

Potential settlement terms or a quick dismissal could limit long‑term impact; the company's strong cash position may absorb fines.

Relevance 7/10Novelty 7/10Timing: immediate

Background

The article reports a new multi‑state privacy lawsuit filed by the FTC and several states, including Wisconsin, against Hims & Hers Health Inc.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Wisconsin joins a federal privacy lawsuit alleging Hims & Hers shared sensitive health data with third‑party advertisers.

Expected impact

downward pressure as the market prices in litigation risk and possible regulatory penalties

Evidence & confidence

First‑report of a multi‑state FTC‑backed privacy suit; investors typically react negatively to new enforcement actions.

Market effects

Raises privacy‑compliance concerns for the broader telehealth and digital health sector.

U.S. investors may reassess exposure to health‑tech firms subject to FTC scrutiny.

Highlights growing regulatory focus on data privacy, potentially influencing global health‑tech valuations.

Counterpoint

If Hims & Hers successfully defends the case, the stock could rebound on reduced perceived risk.

Key entities

  • Hims & Hers Health Inc.

    Telehealth provider accused of sharing patient data with advertisers.

  • Wisconsin Attorney General Josh Kaul

    Announced the state's participation in the federal lawsuit.

Related articles

$HIMSMed

Canaccord reiterates Hims & Hers stock rating on peptide launch

Canaccord Genuity reiterated a Buy rating and $40 price target for Hims & Hers Health (HIMS) after its launch of Peptides+ treatment line. The company reported Q3 revenue of $890M, up 49% YoY, but saw a subscriber decline. Analysts have mixed views on its outlook, with some lowering price targets due to subscriber losses and others optimistic about future growth.

$HIMSHighAI 8/10

Should Hims & Hers Stock's Drop After Earnings Worry You?

Hims & Hers Health (HIMS) stock dropped 16.6% after reporting Q3 2026 earnings. Revenue of $890M missed estimates by 2.2%, and EPS was -$0.10 vs. expected $0.06 profit. Subscribers fell by 100,000 to 2.8M. Management cut full-year EBITDA and revenue forecasts, citing marketing adjustments and delayed revenue recognition.

$HIMSMed

Wisconsin joins federal lawsuit against Hims & Hers telehealth provider

Wisconsin joined a federal lawsuit against Hims & Hers Health, alleging the telehealth provider shared customer health data with Meta and Snapchat, and engaged in deceptive subscription practices. The state seeks an injunction and restitution. Hims denies wrongdoing, stating it provides clear information to customers. The FTC and six other states are also involved.

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.